微创技术结合外科手术治疗重症下肢缺血

目的 探讨术中血管微创治疗技术结合外科手术治疗重症下肢缺血的初步临床经验。方法 1999年7月至2000年10月,采用术中同时行髂动脉腔内微创治疗技术(球囊扩张和支架植入)结合肢体远端动脉重建术治疗广泛多节段动脉硬化闭塞症15例(20条肢体)。结果 术中17条髂动脉微创介入治疗均获成功,11条肢体同时行股-腘动脉人工血管旁路术,3条肢体行股-股-腘动脉人工血管旁路系列转流术,5条肢体行股深动脉成形术。其中有1条肢体股-腘动脉旁路术失败。本组患者无重要脏器并发症和手术死亡。平均随访时间8个月(1-16个月),髂动脉腔内支架通畅率100％,3条股-股动脉耻骨上人工血管转流均通畅,而股-腘动脉人工血管通畅率78．6％,截肢率10．0％。结论 术中髂动脉腔内微创介入治疗技术同时结合远端动脉重建术是治疗广泛多节段动脉硬化闭塞症的害全右特肯沸．     

术中髂动脉支架结合股动脉旁路术治疗多节段动脉硬化闭塞症

目的 探讨术中髂动脉腔内成形及支架植入结合股-Guo动脉旁路术治疗多节段动脉硬化闭塞症的初步临床经验。方法 采用术中同时行髂动脉腔内成形和支架植入结合股-Guo动脉旁路术治疗多节段动脉硬化闭塞症10例（12条肢体）。结果 术中11条髂动脉行腔内成形和支架植入均获成功,9条肢体行股-Guo动脉人工血管旁路术,3条肢体行股-股-Guo动脉人工血管旁路系列转流术;1条肢体股-Guo动脉旁路术失败,本组患者无重要脏器并发症和手术死亡。平均随访时间6个月（1-12个月,髂动脉腔内支架通畅率100%;3条股-股动脉耻骨上人工血管转流均通畅;而股-Guo动脉人工血管通畅率83.3%;截肢率8.3%。结论 术中髂动脉腔内支架结合股-Guo动脉旁路术是治疗多节段动脉硬化闭塞症的安全、有效方法。     

解剖外腋-股、股-股动脉旁路移植术治疗主髂动脉闭塞症

目的探讨解剖外腋股、股股动脉旁路移植术治疗主髂动脉闭塞症的疗效。方法采用解剖外旁路移植术治疗主髂动脉闭塞症患者３２例。１８例腹主动脉或两侧髂动脉闭塞者采用腋股动脉旁路术，其中２例为腋两股动脉旁路术；１４例单侧髂动脉闭塞者采用股对侧股动脉旁路术。采用腋股动脉旁路的患者，术中８例用真丝人造血管移植，１０例用聚四氟乙烯（ＧｏｒｅＴｅｘ）人造血管；股股动脉旁路术中６例用真丝人造血管移植，１例用自体大隐静脉，７例用ＧｏｒｅＴｅｘ人造血管。结果术后５年随访时，股股动脉旁路术通畅率为７８％，其中真丝人造血管与ＧｏｒｅＴｅｘ人造血管通畅率无明显差异；腋股动脉旁路术中，８例真丝人造血管均已闭塞，１０例ＧｏｒｅＴｅｘ人造血管中１例闭塞，１例发生腹股沟部假性动脉瘤。结论解剖外动脉旁路移植术操作简单，创伤小，无腹部手术并发症，手术安全，术后恢复快。真丝人造血管的使用应限于短段的股股动脉旁路术     

剖解外腋—股,股—股动脉旁路移植术治疗主髂动脉闭塞症

目的 探讨剖解外腋－股、股－股动脉旁路移植术治疗主髂动脉闭塞症的疗效。方法 采用解剖外旁路移植术治疗主骼动脉闭塞症患者３２例。１８例腹主动脉或两侧髂动脉闭塞者采用腋－股动脉旁路术,其中２例为腋－两股动脉旁路术;１４例单侧髂动脉闭塞者采用股－对侧股动脉旁路术。采用腋－肌动脉旁路的患者,术中８例用真丝人造血管移植,１０例四氟乙烯（Ｇｏｒｅ－Ｔｅｘ）人造血管;股－股动脉旁路术中６例用真丝人造血管移植,１     

267例主髂动脉闭塞的手术治疗经验

目的 探讨肾动脉开口水平以下腹主动脉闭塞及髂动脉闭塞的手术方式选择及治疗经验。方法 回顾性分析267例主、髂动脉闭塞患者的临床资料。结果 267例患者全部行手术治疗。行腹主动脉－髂（股）动脉人工血管转流术145例,髂动脉－股动脉人工血管转流术40例,股动脉－股动脉人工血管转流术45例,腋动脉－股动脉人工血管转流术37例。总有效率为96．5％,围手术期病死率为3．5％。267例中178例得到随访,平均随访时间5年9个月,人工血管通畅率为82．0％。结论 符合正常血液动力学手术的主要术式是腹主动脉－（双）髂、股动脉人工血管转流术,对于年老、体弱者,特别是全身一般状况较差,伴有冠心病、高血压、脑动脉硬化、脑梗塞等慢性疾病的患者,应采用腋动脉－（双）髂股动脉人工血管转流术或股动脉－股动脉人工血管转流术,可明显减低手术病死率。     

动脉旁路手术治疗慢性下肢缺血的中远期结果

目的 探讨慢性下肢缺血的动脉旁路治疗的中远期效果.方法 回顾性分析2002年1月至2007年4月212例经动脉旁路治疗的慢性下肢缺血患者的临床资料.治疗方式包括股.膝上腘动脉旁路111例,股-膝下胭动脉旁路59例,主-髂动脉旁路25例,股股转流17例.结果 术后186例(87.7%)获随访6～68个月(中位随访期18个月),股-膝上胭动脉旁路术与股-膝下胭动脉旁路术1年初次通畅率分别为69.7%、53.5%,二次累计通畅率为81.6%、60.5%,两者差异无统计学意义(P＞0.05);其3年通畅率分别为56.3%和23.8%,两者差异有统计学意义(P＜0.05);腹主-髂股旁路与股一膝上胭动脉旁路及股股转流术近远期通畅率差异均无统计学意义(P＞0.05).随访期内52例患者行二次手术,23例行膝上或膝下截肢,保肢率为89.2%.围手术期死亡10例(4.7%),随访死亡20例,多数死于心脑血管原发疾病;人工血管感染6例.结论 根据患者病情选用适当的旁路手术方式,可取得满意的效果.股-膝上腘动脉旁路中、远期通畅率高于股-膝下胭动脉旁路,两者近期通畅率无差异.     

解剖外旁路手术治疗高龄患者主髂动脉闭塞症

目的 评价解剖外途径动脉旁路术治疗高龄重症主髂动脉闭塞的临床效果.方法 回顾性分析2005年1月至2008年12月采用解剖外路径动脉旁路术治疗的高龄重症主髂动脉闭塞33例(39条肢体),男性26例,女性7例,平均年龄76.0±3.0岁(70～87岁),临床症状按照Fontaine分期为Ⅱb期5例(7条肢体),Ⅲ期22例(26条肢体),Ⅳ期6例(6条肢体),均为TASC C～D级病变.结果 腋-双股动脉旁路术6例(12条肢体),腋-单股动脉旁路术20例(20条肢体),股-股耻骨上旁路术7例(7条肢体).术后22例静息痛消失,5例患者间歇跛行明显改善,6例患者肢端溃疡愈合.踝肱比从术前的0.29 ± 0.11提高到0.66 ±0.13,差异有统计学意义(t=2.69,P＜0.05).术后并发症发生率9.1%(3/33),无30d内截肢和死亡病例.本组33例患者均获随访,随访率100%.术后随访时间6～28个月,平均(12±5)个月,随访期间内移植物一期通畅率89.7%(35/39),二期通畅率94.9%(37/39),肢体救治率92.3%(36/39),死亡率6.1%(2/33),死亡原因分别为心肌梗死及恶性肿瘤(胃癌).结论 解剖外旁路术是治疗高龄重症主髂动脉闭塞的安全有效方法,术前心肺功能不全是高龄患者围手术期并发症的主要危险因素.     

下肢动脉硬化性闭塞症的外科治疗

自１９８８年１月至１９９２年１２月，我们共收治下肢动脉硬化性闭塞症２７例，涉及３８条肢体。男性２５例，女性２例，年龄４７～７２岁。动脉闭塞的部位以髂总、髂外动脉到股浅动脉这一段最多，占６８．％；其次为腹主动脉到双髂动脉，占２６．３％。全部病例均作了动脉旁路移植术；腹主－髂或股动脉、髂册和股－动脉等方式。手术治疗总有效率８６．８％；其中显效７６．３％。无效和恶化者１３．２％，多因远侧动脉有广泛狭窄和闭塞所致；这类病人不宜作动脉旁路移植术。在股总或股浅动脉闭塞时，应尽量利用股深动脉，作股深动脉成形术或腹主动脉＋股深动脉人工血管搭桥术。作股－动脉搭桥时，常用大隐静脉，需注意其厚度能否耐受动脉高压，以免以后破裂引起大出血。     

腹腔镜下左髂总动脉-股动脉人工血管旁路移植治疗髂外动脉闭塞症一例

目的总结腹腔镜下人工血管旁路移植治疗髂外动脉闭塞症的手术技巧和临床效果。方法 2011年12月,收治1例57岁髂外动脉硬化闭塞症男性患者。患者双下肢间歇性跛行;下肢动脉造影示左髂外动脉闭塞,右髂总动脉狭窄;心电图示窦性心律,完全性右束支传导阻滞,ST段改变;踝肱指数(ankle brachial index,ABI):左侧0.59,右侧0.54。于全麻下行腹腔镜下左髂总动脉-股动脉人工血管旁路移植术。结果术后人工血管通畅,吻合口无漏血,患者跛行症状明显改善。术后1周左侧ABI增加至1.09;术后1个月血管造影显示血管通畅。结论腹腔镜下主-髂动脉重建既保留开腹动脉旁路移植效果好的特点,又具有腔内支架成形创伤小、术后恢复快的优点。     

股深动脉成形联合髂动脉支架治疗高危重症下肢缺血18例

目的：探讨股深动脉成形联合髂动脉支架植入治疗高危、重症下肢动脉闭塞缺血的效果。方法：对18例（26条肢体）重症、高危下肢动脉广泛闭塞患者采用术中髂动脉球囊扩张和支架植入联合股深动脉成形术治疗。通过观察患肢间歇性跛行距离,踝肱指数等指标改善情况进行评估。结果：髂动脉球囊扩张和支架植入20条肢体、股深动脉成形22条肢体、股-股动脉人工血管转流6条肢体均获得成功,平均随访（16±8.5）个月（3～26个月）,踝肱指数明显提高,静息痛均消失。结论：股深动脉成形联合髂动脉支架植入是治疗高危、重症下肢动脉硬化闭塞症的安全、有效方法。     

Reduction of Plasma Fibrinogen, Immunoglobulin G, and Immunoglobulin M Concentrations by Immunoadsorption Therapy with Tryptophan and Phenylalanine Adsorbents

Abstract Immunoadsorption (1A) therapy with tryptophan (TR-350) or phenylalanine (PH-350) adsorbents has been used to reduce the concentration of serum antibodies in human lymphocyte antigen (HLA)-immunized patients. Other forms of plasma purification have been reported to reduce the level of fibrinogen, which affects the blood properties. In this study we investigated the effects of IA therapy using both adsorbents on plasma fibrinogen and immunoglobulins G and M in 13 patients (8 patients were treated with TR-350, and 5 patients were treated with PH-350). During each session 1 plasma volume (2.8 ± 0.4 L of plasma) was processed through the immunocolumn and then returned to the patient together with the blood cells. Compared with the pretreatment values, the plasma fibrinogen, IgG, and IgM concentrations were significantly reduced after IA therapy (p < 0.01 for TR-350; p < 0.04 for PH-350). There was a positive correlation between the degree of reduction of plasma proteins and the number of IA treatments given. A nonpara-metric test (Wilcoxon's signed-rank test or the Mann-Whitney test) was used for statistical analysis. We conclude from our study that IA therapy effectively lowers the plasma levels of fibrinogen, IgG, and IgM and thus can be considered a valuable alternative to other blood purification methods.     

Is the recovery profile of mivacurium independent of the rate of decay of its plasma concentration in patients with normal plasma cholinesterase activity?

Background: The duration of action of muscle relaxants is poorly correlated to the rate of decay of their plasma concentration. The plasma concentration of mivacurium may rapidly decrease below its active concentration because of the extensive hydrolysis of mivacurium. By inflating a tourniquet on one upper limb for 3 min after the administration of atracurium, mivacurium or vecuronium, we studied the influence of the initial decline of their plasma concentration on their effect. Methods: In 50 patients anaesthetised with thiopental, isoflurane and fentanyl, the effect of bolus doses of 0.15 or 0.25 mg . kg^?1 mivacurium (MIV 15, MIV 25), 0.3 or 0.5 mg . kg^?1 atracurium (ATR 30, ATR 50) and 0.06 or 0.1 mg . kg^?1 vecuronium (VEC 06, VEC 10) were measured on both arms (evoked response of the adductor pollicis to train-of-four stimulation every 12 s), a tourniquet being applied on one arm just before and during 3 min after the muscle relaxant bolus. Results: Tourniquet inflation of 3 min almost abolished the neuromuscular effect of mivacurium. In the vecuronium groups and in the ATR 50 group, tourniquet inflation did not modify the maximum degree of depression of the twitch response. Also, the duration of action of vecuronium was unaffected by the tourniquet. In the ATR 30 group, times to return of the twitch response to 25% (duration 25%) and 75% (duration 75%) of control response were significantly shorter in the cuffed arm, 23 min vs 27 min, and 41 min vs 45 min, respectively. In the ATR 50 group, only duration 25% was significantly shorter in the cuffed arm (41 min vs 45 min). Conclusion: The results suggest that the rate of decline of the plasma concentration of mivacurium is so rapid, that a very low and almost clinically ineffective concentration is present as soon as 3 min after its administration. The results also indicate that the recovery from a mivacurium-induced neuromuscular blockade is not influenced by the rate of decay of its plasma concentration in patients with genotypically normal plasma cholinesterase.     

Membranes in Artificial Organs

Abstract: Membrane processes play a pivotal and enabling role in modern replacement therapy for acute and chronic organ failure and in the management of immunologic diseases. In fact, virtually all contemporary extracorporeal blood purification methods employ membrane devices, and the next generation of artificial organs and tissue engineering therapies are almost certain to be similarly grounded in membrane technology. In this short essay, we comment on the similarities and differences among synthetic membranes and their natural counterparts and also provide a critical overview of the demographics and technology of hemodialysis, hemofiltration, apheresis, oxygenation, and emerging membrane technologies and applications.     

The multiply injured child

Blunt trauma is the principal cause of childhood death in many developed countries. This review outlines the differences between adults and children with respect to resuscitation and treatment of orthopaedic injuries in a child with polytrauma. Recent advances in techniques of fracture stabilization are reported.     

Dilemma of Membrane Biocompatibility and Reuse

Abstract: Numerous articles have been published on the multiple use of dialyzers and on the effect of different reprocessing chemicals and techniques on the dialyzer biocompatibility and performance. The results often appear contradictory, especially those comparing standard biocompatibility parameters. Despite this confusion, a discerning review of the published works allows certain limited conclusions to be drawn. Reprocessing of used hemodialyzers changes the biocompatibility profile of a dialyzer as defined by the parameters complement activation. leukopenia, and cytokine release. The effect of reprocessing depends on the chemicals and reprocessing technique applied and also on the type of membrane polymer being subjected to the reprocessing procedure. Reports of pyrogenic reactions indicate that the flux of the membrane also influences how suitable it is for safe reuse. An increased risk of allergic and pyrogenic reactions appears to be associated with dialyzer reuse. Furthermore, there has been a lack of investigations into the immunologic effect of the layer of adsorbed and chemically altered proteins that remains on the inner surface of reprocessed dialyzers. We conclude that the clinical benefit of dialyzer reuse cannot be generally accepted from a biocompatibility point of view.     

The analgesic effect of racemic ketamine in patients with chronic ischemic pain due to lower extremity arteriosclerosis obliterans

Background : Ketamine in sub-dissociative doses has been shown to have analgesic and phantom-Limb pain, where conventional treatment has often failed. Chronic ischemic pain due to lower extremity arteriosclerosis obliterans often responds poorly to analgesics, and the pain-generating mechanisms are not well understood.
Methods : Eight patients with rest pain in the lower extremity due to arteriosclerosis obliterans were given sub-dissociative doses of 0.15, 0.30, or 0.45 mg/kg racemic ketamine and morphine 10 mg as a 5-min infusion on four separate days in a cross-over, double-blind, randomised protocol. Plasma levels of (S)- and (R)-ketamine and their nor-metabolites were analysed with an enantioselective high-performance liquid chromatography (HPLC) method. Pain levels were evaluated with a visual analogue scale (VAS).
Results : Individual pain levels were highly variable during and after all the infusions but the pooled pain levels showed a dose-dependent analgesic effect of ketamine with a transient but complete pain relief in all patients at the highest dose (0.45 mg/ kg). Side-effects, mainly disturbed cognition and perception, were pronounced and dose-dependent. Morphine 10 mg had an analgesic peak at 20 min and 5/8 patients had complete pain relief. The remaining 3 patients also had high baseline pain scores, indicating a higher analgesic potency for the 0.30 and 0.45 mg/ kg ketamine doses than for morphine 10 mg.
Conclusion : We have demonstrated a potent dose-dependent analgesic effect of racemic ketamine in clinical ischemic pain. Due to a narrow therapeutic window, this analgesic effect is probably best utilised in combination with other analgesics.     

Intravenous endotoxin does not increase tissue extravasation of albumin in rats

Background : It is unclear whether activation of the inducible nitric oxide synthase (iNOS) increases or decreases the extravasation of plasma.
Methods : Chloralose anaesthetised male Wistar rats received E. coli lipopolysacharide (LPS), 3 mg kg^-1 i.v., or the corresponding volume of saline, 3 or 5 h before the end of the experiment. Mean arterial pressure (MAP) and heart rate (HR) were recorded. Tissue clearance of radio-labelled albumin, during the last 2 h of each experiment, was determined by a double-isotope method. In separate animals, the serum concentration of nitrite and nitrate was determined, 5 h after LPS or the solvent.
Main Results : LPS initially decreased MAP and lastingly increased HR. In the 3-h LPS animals (n=8), tissue plasma clearance was lower in the heart and calf muscle and increased only in diaphragm, compared to corresponding control animals (n=8). In the 5-h LPS rats, clearance was lowered (n=8) in the entire gastrointestinal tract and in testes, compared to controls (n=8). The serum nitrite/nitrate concentration was higher in animals given LPS (n=6) than in controls (n=6).
Conclusion : After LPS, tissue clearance of albumin was not increased in any major tissue, in spite of increased serum levels of NO end products. Apparently, after activation of iNOS, the augmented release of NO is not necessarily associated with increased albumin extravasation.     

Adrenaline markedly improves thoracic epidural analgesia produced by a low-dose infusion of bupivacaine, fentanyl and adrenaline after major surgery: A randomised, double-blind, cross-over study with and without adrenaline

Background: Basic pharmacological research indicates that there are synergistic antinociceptive effects at the spinal cord level between adrenaline, fentanyl and bupivacaine. Our clinical experience with such a mixture in a thoracic epidural infusion after major surgery confirms this. The objectives of the present study were to evaluate the effects on postoperative pain intensity, pain relief and side effects when removing adrenaline from this triple epidural mixture. Methods: A prospective, randomised, double-blind, cross-over study was carried out in 24 patients after major thoracic or abdominal surgery. Patients with only mild pain when coughing during a titrated thoracic epidural infusion of about 10 ml · h^?1 of bupivacaine 1 mg · ml^?1, fentanyl 2 μg · ml^?1, and adrenaline 2 μg · ml^?1 were included. On the 1^st and 2^nd postoperative days each patient was given a double-blind epidural infusion, at the same rate, with or without adrenaline. The effect was observed for 4 h or until pain when coughing became unacceptable in spite of a rescue analgesic procedure. Rescue analgesia consisted of up to two epidural bolus injections per hour and i.v. morphine if necessary. All patients received rectal paracetamol 1 g, every 8 h. Fentanyl serum concentrations were measured with a radioimmunoassay technique at the start and end of each study period. Main outcome measures were extent of sensory blockade and pain intensity at rest and when coughing, evaluated by a visual analogue scale, a verbal categorical rating scale, the Prince Henry Hospital pain score, and an overall quality of pain relief score. Results: The number of hypaesthetic dermatomal segments decreased (P <0.001) and pain intensity at rest and when coughing increased (P <0.001) when adrenaline was omitted from the triple epidural mixture. This change started within the first hour after removing adrenaline. After 3 h pain intensity when coughing had increased to unacceptable levels in spite of rescue analgesia (epidural bolus injections and i.v. morphine). Within 15–20 min after restarting the triple epidural mixture with adrenaline, pain intensity was again reduced to mild pain when coughing. Serum concentration of fentanyl doubled from 0.22 to 0.45 ng · ml^?1 (P <0.01), and there was more sedation during the period without adrenaline. Conclusions: Adrenaline increases sensory block and improves the pain-relieving effect of a mixture of bupivacaine and fentanyl infused epidurally at a thoracic level after major thoracic or abdominal surgery. Serum fentanyl concentrations doubled and sedation increased when adrenaline was removed from the epidural infusion, indicating more rapid vascular absorption and systemic effects of fentanyl.